You are here

Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers

Last updated on December 15, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Orlando, Florida, 32809 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Body Mass Index (BMI) 30 to 40 kg/m2 and total body weight of >110 lbs.

- Otherwise healthy

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women must be of non-childbearing potential.

- Significant current or history of medical illness.

NCT00479492
Pfizer
Completed
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Morbid Obesity, Metabolic Disease
NCT00283374
All Genders
18+
Years
Multiple Sites
Obesity, Smoking, Dyslipidemia, Diabetes Mellitus, Hypertension
NCT01243138
All Genders
18+
Years
Multiple Sites
Obesity
NCT03041792
All Genders
18+
Years
Orlando, Florida
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
A 12-Week, Randomized, Subject And Investigator Blind, Placebo-Controlled Trial To Evaluate The Effect Of CP-866,087 On Weight Loss In Obese, Otherwise Healthy Adult Subjects
The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Obesity
  • Drug: CP-866,087
    1 mg of CP-866,087, administered QD for 84 days
  • Drug: CP-866,087
    5 mg of CP-866,087, administered QD for 84 days
  • Drug: CP-866,087
    10 mg of CP-866,087, administered QD for 84 days
  • Drug: placebo
    placebo administered QD for 84 days
  • Experimental: 1
    Intervention: Drug: CP-866,087
  • Experimental: 2
    Intervention: Drug: CP-866,087
  • Experimental: 3
    Intervention: Drug: CP-866,087
  • Placebo Comparator: 4
    Intervention: Drug: placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
94
January 2008
January 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Body Mass Index (BMI) 30 to 40 kg/m2 and total body weight of >110 lbs.
  • Otherwise healthy

Exclusion Criteria:

  • Women must be of non-childbearing potential.
  • Significant current or history of medical illness.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00479492
A5051019
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now